Browse the corpus

Lymphogranuloma venereum is a sexually transmitted infection (STI) caused by Chlamydia trachomatis, specifically the L1, L2, and L3 serovars, which differ from those responsible for more common Chlamydia infections. Lymphogranuloma venereum tends to cause more severe inflammation and more aggressive infections compared to C trachomatis disorders from serovars A-K, where the resulting disease is typically relatively mild or asymptomatic. C trachomatis is a nonmotile, gram-negative intracellular bacterium that is transmissible through anal, oral, urethral, or vaginal contact. The bacterium is most frequently encountered in men who have sex with other men and is closely associated with HIV infections. Lymphogranuloma venereum most commonly presents with proctocolitis, which can be an invasive, systemic infection and progress to strictures, colorectal fistulas, rectal discharge, pain in the anus, tenesmus, and fever. Lymphogranuloma venereum is rare in the United States but is commonly found in subtropical and tropical regions worldwide. Lymphogranuloma venereum–specific PCR-based testing confirms the diagnosis of lymphogranuloma venereum, but this may not be widely available. Therefore, the diagnosis is typically based on the history and physical findings, regional prevalence, nucleic acid amplification testing for C trachomatis from the affected anatomical site, clinical suspicion, and the exclusion of other etiologies. Patients presenting with severe proctocolitis symptoms, especially in endemic areas, should have a rectal specimen tested by nucleic acid amplification testing for C trachomatis. The Centers for Disease Control and Prevention recommends that all patients presenting with proctocolitis undergo appropriate diagnostic testing. The recommended treatment for lymphogranuloma venereum is antibiotic therapy, with doxycycline 100 mg twice daily for 21 days as the preferred regimen. Alternatives include erythromycin 500 mg four times daily for 21 days or azithromycin 1 g weekly for 3 weeks, both of which are acceptable during pregnancy. This activity summarizes the history, epidemiology, pathophysiology, evaluation, and management of lymphogranuloma venereum infections, including proctocolitis. This activity also emphasizes the role of clinicians in the timely identification, diagnosis, and treatment of patients with this serious infection. Objectives:

The recommended treatment for lymphogranuloma venereum is antibiotic therapy, with doxycycline 100 mg twice daily for 21 days as the preferred regimen. Alternatives include erythromycin 500 mg four times daily for 21 days or azithromycin 1 g weekly for 3 weeks, both of which are acceptable during pregnancy. This activity summarizes the history, epidemiology, pathophysiology, evaluation, and management of lymphogranuloma venereum infections, including proctocolitis. This activity also emphasizes the role of clinicians in the timely identification, diagnosis, and treatment of patients with this serious infection. Objectives: Determine the etiology of lymphogranuloma venereum infections, including proctocolitis. Identify the underlying pathophysiology and histopathology of lymphogranuloma venereum infections. Assess the risk factors, clinical presentation, diagnostic approaches, and treatment strategies for lymphogranuloma venereum infections. Collaborate with the interprofessional team to prevent disease outbreaks by educating patients on safe sexual practices, improving early identification of the disease, and preventing transmission to sexual partners. Access free multiple choice questions on this topic.

Lymphogranuloma venereum is a sexually transmitted infection (STI) caused by Chlamydia trachomatis, specifically the L1, L2, and L3 serovars, which differ from those responsible for more common Chlamydia infections.[1][2][3] Among these, L2b is the most common serovar of C trachomatis that is responsible for causing lymphogranuloma venereum.[4][5] Lymphogranuloma venereum tends to cause more severe inflammation and more aggressive infections compared to C trachomatis disorders from serovars A-K, where the resulting disease is typically relatively mild or asymptomatic.[3][6][7] Lymphogranuloma venereum is rare in the United States compared to other STIs, such as gonorrhea, syphilis, or the more common but less severe chlamydia infections caused by serovars A-K.[2] However, accurate data on the prevalence and incidence of lymphogranuloma venereum are unavailable due to inadequate evaluations, misdiagnoses, diagnostic difficulties, and limited reporting requirements.[1][2] In August 2018, the Centers for Disease Control and Prevention (CDC) presented data at the National STD Prevention Conference showing that STIs continue to rise at alarming rates. In 2023, nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States, surpassing the previous record set in 2016 by more than 300,000 cases. With the rise in transmission of STIs, rare diseases once considered eradicated have resurfaced. Lymphogranuloma venereum is one such example, although accurate data on its prevalence and incidence are unavailable due to inadequate evaluations, misdiagnoses, diagnostic difficulties, and limited reporting requirements.[1][2][8][9] First described in 1833 by Wallace and later by Durand, Nicolas, and Favre in 1913, the infection was initially considered to be climatic in origin and identified as tropical bubo.[10][11] It was not until 1912 that Rost concluded that the disease was venereal in origin.[12]

With the rise in transmission of STIs, rare diseases once considered eradicated have resurfaced. Lymphogranuloma venereum is one such example, although accurate data on its prevalence and incidence are unavailable due to inadequate evaluations, misdiagnoses, diagnostic difficulties, and limited reporting requirements.[1][2][8][9] First described in 1833 by Wallace and later by Durand, Nicolas, and Favre in 1913, the infection was initially considered to be climatic in origin and identified as tropical bubo.[10][11] It was not until 1912 that Rost concluded that the disease was venereal in origin.[12] Lymphogranuloma venereum presents with variable clinical manifestations depending on the site of bacterial inoculation.[13] The condition primarily affects the lymphatic system and lymph nodes. Classically, the infection characteristically presented with the development of self-limited genital ulceration and painful inguinal adenopathy or buboes.[13] If left untreated, the disease process was progressive and destructive, with systemic spread leading to several extra-genital manifestations.[13] With the advent of antibiotic therapy, lymphogranuloma venereum had largely disappeared from Western society.[14] However, since 2003, outbreaks of lymphogranuloma venereum have emerged in Western Europe, Australia, and North America, disproportionately affecting men who have sex with men (MSM), and the worldwide incidence is increasing.[15][16][17][18][19]

The risk of developing lymphogranuloma venereum is related to lifestyle and sexual practices. Acute infection requires direct inoculation of the C trachomatis bacteria into the host tissue. In the case of lymphogranuloma venereum proctocolitis, infection transmission is often through receptive anal intercourse. As with other STIs, promiscuity and intercourse with multiple partners place individuals at increased risk for contracting the disease. As lymphogranuloma venereum proctocolitis has disproportionately affected homosexual men, studies have attempted to identify risk factors or behavioral patterns within this population that place an individual at increased risk for developing lymphogranuloma venereum. Using questionnaires to identify differences between asymptomatic and symptomatic homosexual men, the study found that those with lymphogranuloma venereum infections were more likely to have had unprotected receptive or insertive anal intercourse, including fisting; have had multiple partners or one-off sexual encounters; have concurrent recreational drug and alcohol use (gamma-hydroxybutyrate and methamphetamines most commonly reported); and have used shared sex toys.[20][21][22]

Chlamydia is the most commonly reported infectious disease to the CDC, with more than 209,000 cases of syphilis, over 600,000 cases of gonorrhea, and over 1.6 million cases of chlamydia. C trachomatis is also the most common sexually transmitted disease worldwide, with over 100 million new cases annually, and the incidence is increasing.[23][24][25] Lymphogranuloma venereum is still relatively rare in the United States, although the incidence is increasing.[26] This condition is most commonly found in subtropical and tropical regions worldwide, such as Africa, India, Southeast Asia, South America, and the Caribbean, where it has primarily been a heterosexual disease.[2][27] Lymphogranuloma venereum is estimated to account for 2% to 10% of all genital ulcers in Africa and Southeast Asia, with transmission believed to be primarily through asymptomatic carriers.[10][28][29] Lymphogranuloma venereum infections are frequently associated with HIV and other STIs.[14][30][31] In Western countries, lymphogranuloma venereum is disproportionately found among men with HIV who have sex with men, in whom it is considered endemic.[2][14] Conversely, the majority of patients with lymphogranuloma venereum are likely to be HIV-positive.[14] Lymphogranuloma venereum most commonly presents in Western countries with proctocolitis, which can be an invasive, aggressive, systemic infection that can progress to strictures, colorectal fistulas, rectal discharge, anal pain, tenesmus, and fever.[32] Genital involvement of lymphogranuloma venereum in MSM populations is quite uncommon despite the high prevalence of lymphogranuloma venereal proctocolitis in this group.[33] Prior to 2003, lymphogranuloma venereum was rare in the Western world and was primarily endemic to tropical regions, such as East and West Africa, India, Southeast Asia, and the Caribbean, with a low prevalence in the industrialized world.[34] As such, the Council of State and Territorial Epidemiologists, with input from the CDC, voted to cease mandated reporting of the disease in 1995.[35]

Prior to 2003, lymphogranuloma venereum was rare in the Western world and was primarily endemic to tropical regions, such as East and West Africa, India, Southeast Asia, and the Caribbean, with a low prevalence in the industrialized world.[34] As such, the Council of State and Territorial Epidemiologists, with input from the CDC, voted to cease mandated reporting of the disease in 1995.[35] In 2003, an outbreak of lymphogranuloma venereum proctitis amongst HIV-positive MSM in Rotterdam, the Netherlands, occurred, which prompted a concerted effort to warn the international medical community.[18][36][37] Subsequent published case reports demonstrated the presence of lymphogranuloma venereum proctitis in multiple large European cities.[17][38] Western Europe and North American countries began to implement surveillance protocols amongst high-risk patients. Despite these efforts, a decade later, mandatory reporting of lymphogranuloma venereum was still not required in several European countries. Even today, only 24 states in the United States mandate the reporting of lymphogranuloma venereum cases to the CDC, which limits the available data to determine the true disease prevalence. Accurate epidemiologic figures remain elusive, as it is still not universally mandated or required to report cases of lymphogranuloma venereum. Moreover, as noted in the 2016 European Centre for Disease Prevention and Control (ECDC) annual epidemiological report, present surveillance strategies focus primarily on high-risk populations, such as MSM and patients with HIV/AIDS or other STIs, making it difficult to generate data applicable to the general population. Although determining the incidence and prevalence of lymphogranuloma venereum has been challenging, data reflect a disease on the rise that disproportionately affects MSM.[14][18] The ongoing data collection published by the ECDC has continued to show a rise in the incidence of lymphogranuloma venereum. In 2014, ECDC data compiled from 21 reporting European countries revealed 1416 reported cases that year alone, a 32% increase from 2013. The vast majority of cases reported in the ECDC data (87%) were noted to be from France, the Netherlands, and the United Kingdom, with almost all cases reported being among MSM.

The ongoing data collection published by the ECDC has continued to show a rise in the incidence of lymphogranuloma venereum. In 2014, ECDC data compiled from 21 reporting European countries revealed 1416 reported cases that year alone, a 32% increase from 2013. The vast majority of cases reported in the ECDC data (87%) were noted to be from France, the Netherlands, and the United Kingdom, with almost all cases reported being among MSM. A population-based incidence study conducted in Barcelona from January 2007 to December 2011 revealed a 1032% increase in incidence among MSM during the study period.[39] In the United States, specific data regarding lymphogranuloma venereum have not been available from the CDC. Notably, reported cases of Chlamydia infection in the United States have continued to increase annually, according to CDC surveillance data. Patients with HIV have been disproportionately affected by lymphogranuloma venereum infections.[14] In the ECDC data of patients with a known HIV status, 87% of confirmed lymphogranuloma venereum cases occurred in HIV-positive patients. A 2007 meta-analysis concluded that from 1996 to 2006, HIV-positive MSM accounted for 75% of lymphogranuloma venereum cases on average in Western Europe alone.[40] A prospective, multicenter study in Germany conducted from December 2009 to December 2010 evaluated the prevalence of multiple STIs among MSM. The findings revealed that 58% of patients who tested positive for lymphogranuloma venereum were also HIV-positive.[41] In a 2011 meta-analysis, 13 descriptive studies showed that at least two-thirds of MSM with lymphogranuloma venereum were co-infected with HIV.[14] In the same analysis, pooled data from 17 studies from 2000 to 2009 showed HIV-positive MSM were greater than 8 times as likely to have HIV (OR 8.19, 95% CI 4.68-14.33) than those who had non-lymphogranuloma venereum Chlamydia infections.[14] These data demonstrated an association stronger than other STIs that reemerged during the same timeframe.[14] Improved survival in the post-highly active antiretroviral therapy era and serosorting (the practice of using HIV status as a decision-making strategy when participating in sexual activity) were likely factors contributing to this association.[40]

In a 2011 meta-analysis, 13 descriptive studies showed that at least two-thirds of MSM with lymphogranuloma venereum were co-infected with HIV.[14] In the same analysis, pooled data from 17 studies from 2000 to 2009 showed HIV-positive MSM were greater than 8 times as likely to have HIV (OR 8.19, 95% CI 4.68-14.33) than those who had non-lymphogranuloma venereum Chlamydia infections.[14] These data demonstrated an association stronger than other STIs that reemerged during the same timeframe.[14] Improved survival in the post-highly active antiretroviral therapy era and serosorting (the practice of using HIV status as a decision-making strategy when participating in sexual activity) were likely factors contributing to this association.[40] Other prevalence estimates and case-control studies have shown that HIV-infected MSM are disproportionately affected by the emergence of lymphogranuloma venereum due to an underlying pathophysiologic mechanism. Brenchley et al proposed that acute and chronic HIV infections cause impairment or depletion of effector-type T cells in the gastrointestinal mucosa, resulting in rapid depletion of CD4+ T cells.[42] By decreasing and inhibiting mucosal immune integrity, HIV may facilitate other co-infections, such as syphilis and chlamydia.[43] Moreover, the direct exposure and inoculation of bacteria into the rectal mucosa during receptive anal intercourse facilitates transmission in an already susceptible population. The susceptibility of HIV-infected individuals to acquiring lymphogranuloma venereum proctitis is likely a combination of high-risk sexual behavior and T-cell immunodeficiency.[42][43]

C trachomatis is a nonmotile, gram-negative intracellular bacterium that is transmissible through anal, oral, or vaginal contact and can penetrate skin and mucus membranes.[10][44] The organism is an obligate intracellular pathogen capable of reproducing intracellularly through binary fission.[10] The organism may affect epithelial cells of the mouth and oral cavity, gastrointestinal tract (primarily the rectum), and the urogenital system.[23][24] Bacterial growth creates perinuclear microcolonies, which proliferate, eventually causing cell lysis.[10] The bacteria then spread through the lymphatics, creating lymphangitis. The clinical course of the disease depends on the site of bacterial inoculation. From the inoculation site, C trachomatis passes through lymphatic channels. C trachomatis penetrates and multiplies within the mononuclear phagocytes inside lymph nodes as it passes through them, inducing a severe lymphoproliferative reaction.[2][10][45] Infectivity is mediated by the organism binding to epithelial cells through a heparin sulfate–like ligand.[45] Infected lymph nodes develop a severe inflammatory reaction and progress to lymphangitis with painful buboes, which ulcerate, creating fistulas, abscesses, and strictures.[46] These lesions can extend into neighboring areas, such as the rectum, leading to fistulas, perirectal abscess formation, proctitis, fibrosis, and anal strictures.[46] Lymphogranuloma venereum can cause a broad spectrum of human diseases, generally involving the genitourinary tract, female reproductive organs (salpingitis), gastrointestinal tract (proctocolitis), joints, and lungs.[10]

Histopathologic findings are often nonspecific, and distinguishing lymphogranuloma venereum from other inflammatory or infectious etiologies may be challenging. For example, lymph node biopsies are typically nonspecific. However, large intracytoplasmic basophilic inclusion bodies, called Gamna-Favre bodies, may be observed in affected endothelial cells of patients with lymphogranuloma venereum. These inclusion bodies are made of degenerated nuclear material and are only found in lymphogranuloma venereum. On rectal biopsy, inflammation, cryptitis, and crypt abscesses are common histologic findings. Cryptitis, crypt abscess formation, increased inflammatory cells in the lamina propria, granuloma formation, and transmural inflammation may be evident.[47] Rectal crypt architectural distortion may be present but is relatively uncommon. These findings can render a histopathologic diagnosis indistinguishable from that of inflammatory bowel disease. Therefore, it is reasonable to ask pathologists to rule out viral etiologies such as herpes simplex virus, cytomegalovirus, and other sexually transmitted infectious agents. Nucleic acid amplification testing for lymphogranuloma venereum is often required for a diagnosis.

Clinically, lymphogranuloma venereum is primarily a lymphatic infection that typically progresses through 3 stages. During the disease course, patients may experience symptoms from the initial infection, systemic dissemination, or the development of chronic inflammation. Symptoms vary depending on the stage at which a patient presents and the site of bacterial inoculation (see Table. Differential Diagnosis of Lymphogranuloma Venereum Proctocolitis). Transmission of the infection is by anal, oral, or vaginal sexual activity. High-risk factors for lymphogranuloma venereum infections include the following: Being born to a mother known to have chlamydia. Engage in anal or oral group sex without appropriate barrier protection. Having sexual activity without condom protection. Individuals with HIV-positive, gonorrhea, or hepatitis C. Lower socioeconomic status. MSM who represent the group at the highest overall risk. Multiple sexual partners (more than 2 within the past year). Past medical history of a sexually transmitted illness. Recent travel to an area where lymphogranuloma venereum is endemic. Sexually active individuals between the ages of 15 and 40 are the highest-risk age group. Other known high-risk activities include anonymous sexual partnering, street involvement, history of substance abuse, and engaging in high-risk activities, such as fisting. Primary Lymphogranuloma Venereum Primary lymphogranuloma venereum typically develops after an incubation period of 3 to 30 days, during which the first manifestations of the disease may become apparent.[2][10] A transient painless erosion, nodule, papule, pustule, or ulcer frequently forms on the external genitalia at the inoculation site; this stage often passes unnoticed (see Image. Lymphogranuloma Venereum).[13] Possible inoculation sites include the male and female genitalia, penis, vagina, cervix, anus, and oral cavity.[2] The resurgence of lymphogranuloma venereum has disproportionately affected men who have anal intercourse. As such, most new cases (approximately 96% in earlier estimates) present signs and symptoms of proctitis as their initial symptom.[48]

Primary lymphogranuloma venereum typically develops after an incubation period of 3 to 30 days, during which the first manifestations of the disease may become apparent.[2][10] A transient painless erosion, nodule, papule, pustule, or ulcer frequently forms on the external genitalia at the inoculation site; this stage often passes unnoticed (see Image. Lymphogranuloma Venereum).[13] Possible inoculation sites include the male and female genitalia, penis, vagina, cervix, anus, and oral cavity.[2] The resurgence of lymphogranuloma venereum has disproportionately affected men who have anal intercourse. As such, most new cases (approximately 96% in earlier estimates) present signs and symptoms of proctitis as their initial symptom.[48] Following invasion of the rectal mucosa by C trachomatis, patients may present with anorectal bleeding, mucoid and purulent anal discharge, rectal pain, tenesmus, and a change in bowel habits, including constipation.[2][48] Cross-sectional imaging may reveal colorectal wall thickening, and gross endoscopic findings can mimic those of acute infectious proctocolitis or an acute flare of inflammatory bowel disease. Endoscopic findings may include mucosal edema, erythema, and ulceration. Endoscopic biopsies performed during this phase often yield nonspecific findings of inflammation, such as cryptitis and crypt abscess formation. The initial presentation may be a presumed infectious colitis refractory to traditional first-line antibiotic therapy and new-onset rectal bleeding. Underlying malignancy must be ruled out. Secondary Lymphogranuloma Venereum Secondary lymphogranuloma venereum occurs 2 to 6 weeks after initial exposure to the pathogen as the C trachomatis bacteria invade the lymphatic system.[2][10] Painful inguinal and femoral lymphadenopathy (buboes) may develop, which is often the primary clinical symptom as infected regional lymph nodes become firm, swollen, and sore.[2][6] Systemic spread through the lymphatic system can lead to constitutional symptoms, including fever, chills, generalized malaise, myalgias, arthralgias, pneumonitis, and hepatitis, which may be accompanied by abnormal liver enzymes.[2]

Secondary lymphogranuloma venereum occurs 2 to 6 weeks after initial exposure to the pathogen as the C trachomatis bacteria invade the lymphatic system.[2][10] Painful inguinal and femoral lymphadenopathy (buboes) may develop, which is often the primary clinical symptom as infected regional lymph nodes become firm, swollen, and sore.[2][6] Systemic spread through the lymphatic system can lead to constitutional symptoms, including fever, chills, generalized malaise, myalgias, arthralgias, pneumonitis, and hepatitis, which may be accompanied by abnormal liver enzymes.[2] An inguinal syndrome may occur in some patients who have concurrently developed genital lymphogranuloma venereum infections. Classically, the inguinal syndrome was the first manifestation of disease in heterosexual males affected by genital lymphogranuloma venereum. The majority of cases present with unilateral painful inguinal lymph node enlargement and abscess formation. Involvement may be limited to isolated lymph nodes or groups of nodes, which can coalesce into a swollen, necrotic, purulent, and fluctuant mass known as a bubo.[2] One-third of buboes may rupture, while the rest develop into solid masses.[2] Merged regional lymph nodes may also develop into abscesses, which can form sinus tracts if they rupture.[2] Depending on the inoculation site, this process may occur in the intra-abdominal, retroperitoneal, femoral, inguinal, or cervical lymph node chains.[2][49] The groove sign, first described by Greenblatt in 1953, is pathognomonic of genital lymphogranuloma venereum but is present in less than 20% of cases.[49][50][51] This sign—sometimes called Greenblatt's sign—develops as the tough inguinal ligament is preserved despite the involvement of swollen, bulging, adjacent inguinal (above) and femoral (below) lymph node chains, creating a characteristic groove.[10][50][51] Systemic spread through the lymphatic system can lead to constitutional symptoms, including fever, chills, generalized malaise, myalgias, arthralgias, pneumonitis, and hepatitis, which may be accompanied by abnormal liver enzymes.[2][52] Rare complications of the disease during this stage include myocarditis, aseptic meningitis, and ocular inflammatory diseases.[49] Case reports describe reactive arthritis following confirmation of lymphogranuloma venereum proctocolitis.[53]

Systemic spread through the lymphatic system can lead to constitutional symptoms, including fever, chills, generalized malaise, myalgias, arthralgias, pneumonitis, and hepatitis, which may be accompanied by abnormal liver enzymes.[2][52] Rare complications of the disease during this stage include myocarditis, aseptic meningitis, and ocular inflammatory diseases.[49] Case reports describe reactive arthritis following confirmation of lymphogranuloma venereum proctocolitis.[53] The initial genital ulcer typically resolves before or during this secondary phase of the infection, but symptoms of proctocolitis tend to persist.[2] In lymphogranuloma venereum, proctocolitis manifests as an anorectal syndrome. Hemorrhagic proctitis is the most common current presentation in MSM due to the direct transmission of C trachomatis to the rectal mucosa.[2] This condition can also occur in women who have had rectal exposure to an infected man.[2][46] Direct bacterial dissemination to the deep iliac and perirectal lymph nodes may cause lower abdominal and lower back pain. Lymph node involvement is often less evident in this patient population than in genital lymphogranuloma venereum and may only present as local lymph node prominence on cross-sectional imaging. Tertiary Lymphogranuloma Venereum Tertiary lymphogranuloma venereum, also called genitoanorectal syndrome, is characterized by permanent lymphatic damage and demonstrates progressive, local tissue destruction and chronic inflammation caused by the ongoing, untreated infection.[2] Chronic perirectal lymphatic obstruction can produce hemorrhoid-like swellings called lymphorroids.[2] Proctocolitis is the most common presentation overall, especially in the MSM population and in women who indulge in rectal intercourse.[28] Tertiary lymphogranuloma venereum is more common in women as they typically lack significant symptoms during the primary or secondary lymphogranuloma venereum stages. Fistulas, strictures, and stenosis involving the inguinal glands, genitalia, and rectum may form as a result of chronic lymphangitis and progressive sclerosing fibrosis, sometimes closely mimicking inflammatory bowel disease.[2] Rectal stenosis and perirectal pathology, including abscesses, fistulas, strictures, and ulcers, can develop.

Fistulas, strictures, and stenosis involving the inguinal glands, genitalia, and rectum may form as a result of chronic lymphangitis and progressive sclerosing fibrosis, sometimes closely mimicking inflammatory bowel disease.[2] Rectal stenosis and perirectal pathology, including abscesses, fistulas, strictures, and ulcers, can develop. The characteristic distortion from penile and scrotal edema due to lymphogranuloma venereum has sometimes been described as a saxophone penis.[54] Frozen pelvis syndrome can cause chronic pelvic pain, and some patients may develop genital lymphedema (elephantiasis).[32][55] Persistent lymphogranuloma venereum proctitis can lead to strictures, which may subsequently develop into megacolon.[56] Lymphogranuloma venereum may also be the source of fevers of unknown origin and unexplained rectal pain. Table Table 1. Differential Diagnosis of Lymphogranuloma Venereum Proctocolitis.

The diagnosis of lymphogranuloma venereum is based on clinical history, physical findings, diagnostic suspicion, the presence of lymphogranuloma venereum–risk factors, epidemiologic information, regional prevalence, and a positive nucleic acid amplification testing finding of C trachomatis at the symptomatic anatomic site when other causes for the suspicious abnormalities, such as genital, oral, or rectal ulcers; inguinal lymphadenopathy; or proctitis, have been excluded.[2][6][57][58] Nucleic Acid Amplification Testing Nucleic acid amplification testing is the most sensitive and preferred initial test for suspected C trachomatis infections.[59] This testing is performed on swabs from involved lymph nodes, anogenital ulcers, rectal mucosa, or anogenital lesions and is the initial investigation of choice.[32][55][60][61] Nucleic acid amplification testing techniques include polymerase chain reaction (PCR) amplification, transcription-mediated amplification, or strand displacement amplification.[62][63][64][65][66] These assays demonstrate high sensitivity and specificity (sensitivity from 91.4% to 100% and specificity from 98.3% to 98.8%, depending on the nucleic acid amplification testing technique used) for chlamydia.[67] Nucleic acid amplification testing generally identifies 10% to 50% more chlamydial infections than cultures or other means.[55][68] Not all states currently require mandatory reporting of confirmed lymphogranuloma venereum disease to the appropriate local or state agency, but it should be strongly encouraged. Appropriate samples for lymphogranuloma venereum nucleic acid amplification testing may include: [32][69] A swab of exudate from the base of primary anogenital ulcers A swab from the rectal mucosa when anorectal involvement is suspected Aspirate from enlarged or fluctuant lymph nodes or buboes If no fluctuant nodes are found, a small volume (<0.5 mL) of normal saline may be injected into the node and then aspirated Although PCR testing is definitive and can differentiate lymphogranuloma venereum serovars from other, less morbid chlamydial infections, it is not widely available. Nucleic acid amplification testing can detect all chlamydial infections, is extremely sensitive, and is more widely available, although it cannot distinguish lymphogranuloma venereum–causing chlamydia from the less morbid serovars.[28][59]

Although PCR testing is definitive and can differentiate lymphogranuloma venereum serovars from other, less morbid chlamydial infections, it is not widely available. Nucleic acid amplification testing can detect all chlamydial infections, is extremely sensitive, and is more widely available, although it cannot distinguish lymphogranuloma venereum–causing chlamydia from the less morbid serovars.[28][59] Chlamydial serology testing, including immunoassays and microimmunofluorescence, may confirm elevated antibody levels but is infrequently used clinically to diagnose lymphogranuloma venereum due to limited availability, interpretative difficulties, lack of definitive results, and lack of standardization. Complement fixation testing can demonstrate a strong immune response to lymphogranuloma venereum, with a titer reading >1:64 or a 4-fold increase from baseline being considered diagnostic in patients suspected of having the infection.[2][46][70] Serological testing may be considered when nucleic acid amplification testing or similar methods are not available and can serve as an adjunct to extragenital chlamydia cultures.[55] This testing is typically reserved for patients with a high suspicion of lymphogranuloma venereum infection, such as MSM, those with suggestive symptoms, sexual contact with known or suspected individuals infected with lymphogranuloma venereum, risky sexual behavior, or HIV-positive status.[55] However, serology is not recommended for routine lymphogranuloma venereum testing due to problems with interpretation, including cross-reactivity, high degree of variability in titer levels, and difficulty in evaluating post-therapeutic antibody levels.[55]

Serological testing may be considered when nucleic acid amplification testing or similar methods are not available and can serve as an adjunct to extragenital chlamydia cultures.[55] This testing is typically reserved for patients with a high suspicion of lymphogranuloma venereum infection, such as MSM, those with suggestive symptoms, sexual contact with known or suspected individuals infected with lymphogranuloma venereum, risky sexual behavior, or HIV-positive status.[55] However, serology is not recommended for routine lymphogranuloma venereum testing due to problems with interpretation, including cross-reactivity, high degree of variability in titer levels, and difficulty in evaluating post-therapeutic antibody levels.[55] Despite its technical challenges in certain situations, needle aspiration is the preferred method for obtaining samples for culture. As C trachomatis is an intracellular organism, samples for culture must contain cellular material, as routine bacterial smears and cultures are insufficient to definitively diagnose this organism.[2] Cell cultures are highly specific, but they are technically more difficult and expensive than non-culture testing.[2][59] They also have a relatively low reported sensitivity (60%-80%).[2][59] Incorrect negative results from a rectal chlamydial culture can occur in up to 50% of cases.[55] A positive culture is not always possible, even in known lymphogranuloma venereum infections.[2] When a patient with known risk factors has high clinical suspicion of lymphogranuloma venereum, attempts should be made to identify C trachomatis. As standard nucleic acid amplification testing cannot differentiate the C trachomatis serovars, patients suspected of lymphogranuloma venereum with a positive nucleic acid amplification test for chlamydia should receive the complete antibiotic treatment for lymphogranuloma venereum.[24] Lymphogranuloma Venereum Proctocolitis

When a patient with known risk factors has high clinical suspicion of lymphogranuloma venereum, attempts should be made to identify C trachomatis. As standard nucleic acid amplification testing cannot differentiate the C trachomatis serovars, patients suspected of lymphogranuloma venereum with a positive nucleic acid amplification test for chlamydia should receive the complete antibiotic treatment for lymphogranuloma venereum.[24] Lymphogranuloma Venereum Proctocolitis The diagnosis of lymphogranuloma venereum proctocolitis follows a stepwise approach (see Image. Diagnostic Approach to Lymphogranuloma Venereum Proctocolitis). Initial evaluation includes routine laboratory tests and stool cultures to rule out more common infectious entities, such as Campylobacter, Salmonella, Shigella, Escherichia coli, Streptococcus, Cryptosporidium, and Clostridium difficile. Additionally, testing for sexually transmitted infections such as syphilis, gonorrhea, non-lymphogranuloma venereum strains of chlamydia, and herpes simplex virus is performed.[71] Inflammatory bowel disease and malignancy can present with similar clinical symptoms.[71] Cross-sectional imaging and endoscopic evaluation through sigmoidoscopy or colonoscopy can help identify the extent of the disease and any extraintestinal manifestations. An endoscopic biopsy can be used to rule out viral etiologies, malignancy, or underlying inflammatory conditions. However, endoscopic and histologic findings of lymphogranuloma venereum proctocolitis are often nonspecific and mimic other disease processes.[72] A rectal Gram stain with a high number of white blood cells (>10 WBCs) suggests rectal lymphogranuloma venereum.[21][73] A definitive lymphogranuloma venereum diagnosis can be made only with lymphogranuloma venereum-specific molecular testing (genotyping by nucleic acid amplification testing or PCR testing), which can differentiate lymphogranuloma venereum serovars from less morbid C trachomatis strains in rectal and genital specimens.[24] This differentiation cannot generally be achieved through standard nucleic acid amplification testing.

A rectal Gram stain with a high number of white blood cells (>10 WBCs) suggests rectal lymphogranuloma venereum.[21][73] A definitive lymphogranuloma venereum diagnosis can be made only with lymphogranuloma venereum-specific molecular testing (genotyping by nucleic acid amplification testing or PCR testing), which can differentiate lymphogranuloma venereum serovars from less morbid C trachomatis strains in rectal and genital specimens.[24] This differentiation cannot generally be achieved through standard nucleic acid amplification testing. Following confirmation of infection, it is recommended to identify the L1-L3 serovars, if possible. Lymphogranuloma venereum biovar–specific DNA nucleic acid amplification testing can be performed from the initial anorectal swab sample using PCR-based assays.[32][55][74] If positive, the recommended treatment is a 21-day course of antibiotics. Unfortunately, there is a lack of universal access to biovar-specific confirmatory testing.[34] When nucleic acid amplification testing is unavailable, Chlamydia genus-specific serological assays, such as complement fixation and L-type immunofluorescence, are options; however, these tests exhibit lower sensitivity and specificity. When serovar confirmation is unavailable, clinicians should consider initiating a 21-day course of antibiotic therapy in patients meeting one of the following criteria: [2][24] The presence of proctitis on initial colonoscopy or anoscopy More than 10 WBCs per high-powered field on initial anorectal smear HIV-positive status Although these diagnostic strategies are essential in symptomatic patients, they are also useful in screening asymptomatic, high-risk individuals who engage in receptive anal intercourse. Untreated lymphogranuloma venereum proctitis can lead to serious complications, including rectal and anal strictures, perirectal abscesses, fistulas, and masses that can mimic rectal malignancies.[75][76][77]

Although these diagnostic strategies are essential in symptomatic patients, they are also useful in screening asymptomatic, high-risk individuals who engage in receptive anal intercourse. Untreated lymphogranuloma venereum proctitis can lead to serious complications, including rectal and anal strictures, perirectal abscesses, fistulas, and masses that can mimic rectal malignancies.[75][76][77] The CDC recommends that all patients with acute proctitis be tested for a possible lymphogranuloma venereum infection.[24] Patients with severe symptoms of proctitis and a positive nucleic acid amplification testing for C trachomatis should receive a full course of lymphogranuloma venereum therapy.[24] Anoscopy should be performed, and a gram-stained rectal smear should be examined for leukocytes (≥10 WBCs on a rectal gram-stained smear is suggestive of lymphogranuloma venereum).[21][24][73] In addition, patients should be tested for herpes simplex virus through nucleic acid amplification testing; Neisseria gonorrhoeae by culture or nucleic acid amplification testing; Treponema pallidum using serologic testing and darkfield microscopy, if available; and C trachomatis through nucleic acid amplification testing.[23][24] If available, nucleic acid amplification testing or PCR testing for C trachomatis serovars should be performed to confirm the diagnosis of lymphogranuloma venereum.[24][68][78] Differentiating lymphogranuloma venereum proctocolitis from irritable bowel disease is essential for accurate diagnosis and appropriate management.[2][23][72][79] This task is becoming increasingly challenging due to the rising incidence of lymphogranuloma venereum proctocolitis, especially in high-risk populations. However, the incidence of inflammatory bowel disease is also increasing, and there is substantial overlap in the clinical presentation of the 2 disorders.[2][23][72][80][81] In addition, their endoscopic and histological features are similar.[2][23][72][82][83] Lymphogranuloma venereum proctocolitis may demonstrate nonspecific abscesses, granulomas, and ulcerations.[72][82] If longstanding, fistulas, granulomas, and strictures may develop, closely resembling Crohn disease endoscopically and histologically.[72][83] Nucleic acid amplification testing for C trachomatis is essential for diagnosing lymphogranuloma venereum, along with PCR serovar confirmation, if available.[72][78]

Lymphogranuloma venereum proctocolitis may demonstrate nonspecific abscesses, granulomas, and ulcerations.[72][82] If longstanding, fistulas, granulomas, and strictures may develop, closely resembling Crohn disease endoscopically and histologically.[72][83] Nucleic acid amplification testing for C trachomatis is essential for diagnosing lymphogranuloma venereum, along with PCR serovar confirmation, if available.[72][78] The rate of positive rectal C trachomatis findings is reported as 10% to 15% in the MSM community and 5% to 9% in women.[23][84] Most such patients are asymptomatic, with only 15% to 20% reporting symptomatic proctitis.[23] Patients who test positive for non-lymphogranuloma venereum rectal infections tend to be asymptomatic or have only mild symptoms.[23] Nevertheless, antibiotic treatment is still recommended.[23] All known contacts of individuals infected with lymphogranuloma venereum should be promptly tested and treated. Lymphogranuloma venereum is responsible for 10% to 25% of all rectal infections caused by C trachomatis.[23][85][86][87] Lymphogranuloma venereum proctitis should be considered whenever patients are in a high-risk group, have severe proctocolitis symptoms, or do not respond to standard treatments.[2][47][69]

Current CDC guidelines recommend treating patients with clinical features consistent with lymphogranuloma venereum infection, including proctocolitis, genital ulcer disease, and lymphadenopathy.[88] The mainstay of therapy in lymphogranuloma venereum infection remains antibiotic use. Multiple sources, including those from American, Canadian, UK, and European, recommend first-line therapy with doxycycline 100 mg orally twice daily for 21 days, which provides a cure rate of over 98.5%.[13][32][69][89] Lymphogranuloma venereum requires a longer duration of antibiotic therapy to achieve a cure than other chlamydial infections. This recommendation is based on extensive evidence of clinical cure rates and the finding that lymphogranuloma venereum RNA can be detected for up to 16 days during therapy.[55][89][90] In resistant or intractable cases, prolonged therapy may be needed.[90][91] Erythromycin 500 mg orally 4 times daily can be used for second-line therapy and in pregnant patients.[88][92][93][94][95] Azithromycin 1 g orally once weekly for 3 weeks is an attractive regimen that may improve patient compliance and is recommended during pregnancy; however, no controlled trials currently support the efficacy of this therapy.[96] All current and recent (within 60 days) sexual partners of patients known or suspected to be infected with lymphogranuloma venereum should be screened to prevent reinfection and further spread of the disease.[2][55] Ultimately, prevention and the use of appropriate contraception are points of emphasis during encounters with at-risk patients. A second approach is an option in patients with symptoms consistent with lymphogranuloma venereum proctocolitis. Clinicians can consider initiating empiric therapy with doxycycline 100 mg orally twice daily for 7 days in conjunction with a single intramuscular dose of ceftriaxone 250 mg while laboratory tests are pending. If laboratory testing confirms a Chlamydia infection, doxycycline should be continued for a total of 21 days or longer if the patient continues to manifest symptoms (see Image. Diagnostic Approach to Lymphogranuloma Venereum Proctocolitis).[55] Patients being treated for lymphogranuloma venereum should avoid all sexual contact or intercourse until their antibiotic therapy course is completed and all related symptoms have resolved.[2][55] Management of Contacts, Follow-ups, and Special Patient Situations

A second approach is an option in patients with symptoms consistent with lymphogranuloma venereum proctocolitis. Clinicians can consider initiating empiric therapy with doxycycline 100 mg orally twice daily for 7 days in conjunction with a single intramuscular dose of ceftriaxone 250 mg while laboratory tests are pending. If laboratory testing confirms a Chlamydia infection, doxycycline should be continued for a total of 21 days or longer if the patient continues to manifest symptoms (see Image. Diagnostic Approach to Lymphogranuloma Venereum Proctocolitis).[55] Patients being treated for lymphogranuloma venereum should avoid all sexual contact or intercourse until their antibiotic therapy course is completed and all related symptoms have resolved.[2][55] Management of Contacts, Follow-ups, and Special Patient Situations The CDC recommends presumptive treatment for lymphogranuloma venereum in at-risk individuals presenting with symptoms of proctocolitis, severe inguinal lymphadenopathy with bubo formation, or current or recent genital ulcers when other causes have been ruled out. Patients should be monitored regularly until all signs and symptoms have resolved. Patients diagnosed with lymphogranuloma venereum should undergo repeat testing for chlamydia approximately 3 months after completing therapy. If this is not possible, retesting should be done at least within 1 year. Patients and their sexual partners should also be tested for other sexually transmitted infections such as gonorrhea, syphilis, hepatitis B, hepatitis C, and especially HIV.[2][55]

Patients diagnosed with lymphogranuloma venereum should undergo repeat testing for chlamydia approximately 3 months after completing therapy. If this is not possible, retesting should be done at least within 1 year. Patients and their sexual partners should also be tested for other sexually transmitted infections such as gonorrhea, syphilis, hepatitis B, hepatitis C, and especially HIV.[2][55] Sexual partners and contacts of patients diagnosed with lymphogranuloma venereum should be evaluated, examined, and tested for chlamydial infection.[2][6] This recommendation also applies to contacts of patients with probable lymphogranuloma venereum.[2][6] Asymptomatic partners of patients with lymphogranuloma venereum should be presumptively treated with a standard chlamydia antibiotic regimen of doxycycline 100 mg orally twice daily for 7 days.[97] However, some experts recommend a complete 21-day course of antibiotics for all contacts of confirmed and probable lymphogranuloma venereum infections, as a 7-day treatment course is insufficient for lymphogranuloma venereum.[55][98] This approach exceeds the recommendations in most published guidelines but avoids possible inadequate treatment of lymphogranuloma venereum due to testing inadequacies, patient confusion, non-compliance, missed follow-up appointments, and communication failures.[2][55] Azithromycin at 1 g weekly for 3 weeks is recommended in pregnant patients. Follow-up testing is advised 1 month after completing therapy.[2][6] Asymptomatic patients with lymphogranuloma venereum should also be treated with a 7-day course of 100 mg of doxycycline twice daily; however, some have recommended a complete 21-day course to ensure adequate treatment.[2][6][55][97][98][99] In these cases, a single 1-g dose of azithromycin has been suggested as an alternative regimen; however, its efficacy has also been questioned.[91] Patients with lymphogranuloma venereum who test positive for HIV should receive the same antibiotic regimen for C trachomatis as those without HIV. However, prolonged therapy may be required.

Asymptomatic patients with lymphogranuloma venereum should also be treated with a 7-day course of 100 mg of doxycycline twice daily; however, some have recommended a complete 21-day course to ensure adequate treatment.[2][6][55][97][98][99] In these cases, a single 1-g dose of azithromycin has been suggested as an alternative regimen; however, its efficacy has also been questioned.[91] Patients with lymphogranuloma venereum who test positive for HIV should receive the same antibiotic regimen for C trachomatis as those without HIV. However, prolonged therapy may be required. Surgery is not a primary treatment for lymphogranuloma venereum but may be needed to manage complications such as draining abscesses and buboes, treating fistulas, and managing sinus tracts. Buboes and abscesses with fluctuation are best treated by puncture with a large-bore needle and syringe, as standard surgical incision and drainage procedures are not recommended, as they may lead to the development of permanent fistulas.[10] Residual fibrotic lesions and areas of significant tissue destruction may require formal surgical repair with possible reconstruction of the genitourinary tract.[10] Rectal strictures are generally treated with dilation.

Differential diagnosis of lymphogranuloma venereum includes the following: Primary lymphogranuloma venereum Altered bowel habits, pain, and bloody diarrhea: Dysentery and inflammatory bowel disease Diarrhea or pain: Infectious proctocolitis due to common organisms or other STIs such as Neisseria gonorrhoeae, cytomegalovirus, herpes simplex virus, and Entamoeba histolytica Malignancy Pain and altered bowel habits: Irritable bowel syndrome Rectal pain and bloody output: Hemorrhoids Secondary lymphogranuloma venereum Abnormal liver function tests: Hepatitis Cat-scratch disease Chancroid Constitutional symptoms, myalgias, and arthralgias: Routine infectious colitis and influenza Granuloma inguinale Herpes virus Malignancy: Rectal carcinoma and lymphoma Inflammatory bowel disease Syphilis Tertiary lymphogranuloma venereum Fistula or stricture formation: Inflammatory bowel disease (Crohn's disease, ischemic colitis, and ulcerative colitis) C. difficile megacolon Infective proctitis Post-radiation therapy Malignancy

Prognosis is fair and hinges on prompt recognition of the condition, patient compliance with prolonged antibiotic therapy, and avoidance of high-risk behaviors. Recurrence is possible with repeat exposure.

Complications of lymphogranuloma venereum arise from persistent, untreated infection and typically signify progression to tertiary lymphogranuloma venereum. These complications include the following: Abscess formation Cardiac involvement Cervical swelling Chronic pelvic pain (frozen pelvis syndrome) Colorectal strictures and stenoses Encephalitis (rare) Fistulas, sinus tracts, and ulcers Genital swelling (permanent) Hepatic involvement and hepatitis Infertility Lymphadenopathy Lymphatic blockage with edema and swelling Lymphorrhea Ocular disorders Oral ulcers Pneumonia Prolonged groin and rectal pain Reactive arthropathy Rectal masses Rectal stenosis Rectovaginal abnormalities Salpingitis Scarring

A multidisciplinary approach is often necessary in managing lymphogranuloma venereum. A gastroenterologist may be needed for the initial evaluation of patients presenting with proctocolitis. A gynecologist may be involved in vaginal lesions, salpingitis, and female infertility. A urologist should be consulted for genitourinary issues, and an ENT specialist for oral lesions. Consultation with an infectious disease specialist is necessary for HIV-co-infected patients and those with refractory disease. Late-stage illness may require surgical consultation if fistulas, megacolon, stenoses, or strictures develop.

Early recognition of the signs and symptoms of lymphogranuloma venereum is key to improving outcomes. Delays in diagnosis may be related to disease mimicry or failure to elicit an adequate sexual history from patients on intake. High-risk individuals should receive education on early signs and symptoms, means of transmission, prevention of transmission through safe sexual practices, and risks associated with having multiple sexual partners. In addition, testing should be offered and considered in high-risk, asymptomatic patients or those who present with other STIs.

Universal rectal screening for all patients with proctocolitis can identify an additional 34% of individuals with lymphogranuloma venereum who have asymptomatic disease.[32][47][100] Although high-risk populations more commonly present with lymphogranuloma venereum proctocolitis, it is crucial to remember that heterosexual patients can develop lymphogranuloma venereum proctocolitis through unprotected anal intercourse with an infected individual. Asymptomatic, high-risk individuals may benefit from testing during routine visits at periodic intervals. Partners of individuals infected with lymphogranuloma venereum should be tested and treated if they are found to be positive for the disease. Some experts recommend a complete 21-day course of antibiotic therapy to ensure adequate treatment. Pregnant and lactating women should not be treated with doxycycline during the second and third trimesters due to the risk of discoloration of fetal and newborn teeth and bones.[101][102] Erythromycin is recommended as the first-line treatment in these cases. HIV-co-infected individuals may experience a delay in the resolution of their lymphogranuloma venereum disease and may require prolonged courses of therapy. Inguinal lymphogranuloma venereum may also require a longer duration of antibiotic therapy than the typically recommended 21-day course of doxycycline.[91] Urethral chlamydia infections in MSM may be caused by serovars that require a longer duration of antibiotic therapy than the standard regimen.[91] The incidence of genital involvement in lymphogranuloma venereum is relatively low among MSM, despite a very high rate of lymphogranuloma venereum proctocolitis.[33] Some studies have suggested that the recommended 1-g azithromycin therapy for sexual contacts, as recommended in published guidelines, may be insufficient to prevent lymphogranuloma venereum infections.[91] No vaccine is currently available against C trachomatis. Consistent condom use is the most effective method of primary prevention of lymphogranuloma venereum and other STIs, such as HIV.

Some studies have suggested that the recommended 1-g azithromycin therapy for sexual contacts, as recommended in published guidelines, may be insufficient to prevent lymphogranuloma venereum infections.[91] No vaccine is currently available against C trachomatis. Consistent condom use is the most effective method of primary prevention of lymphogranuloma venereum and other STIs, such as HIV. Identification, notification, testing, and treatment of all sexual contacts of infected individuals are essential for controlling outbreaks and reducing transmission. This process may include notification by public health departments, individual physicians, relying on the primary index patient to notify sexual contacts, and similar methods to screen all individuals who may be infected. Active screening for genital chlamydia infection has been shown to reduce the incidence of pelvic inflammatory disease.[24] When lymphogranuloma venereum is suspected, testing for HIV and other STIs should be performed.[2]

The prevention and treatment of lymphogranuloma venereum infections, particularly proctocolitis, require a collaborative, multispecialty approach, involving nurses and clinicians, as well as support from local outreach programs, local and regional health departments, governmental services, and public health agencies. As evidenced in the early 2000s, the European Surveillance of Sexually Transmitted Infections alert system in Europe successfully provided clinicians with local alerts of disease activity and helped coordinate outbreak control. As prompt recognition is critical, similar systems should be fostered in the United States, and clinicians should be encouraged to report to local agencies. As STIs continue to rise at alarming rates, clinicians across all specialties must continue to educate patients on safe sexual practices and how to identify the signs and symptoms of the disease. Initiating and supporting high-risk community outreach groups and screening initiatives for high-risk populations may help reduce the stigma associated with testing and promote eradication. Overall, lifestyle choices, sexual preferences, and HIV co-infection remain the strongest risk factors for developing lymphogranuloma venereum. Frequent reiteration of safe practices by multiple providers across multiple specialties may reinforce the importance of and promote ongoing healthy patient practices. The diagnosis and management of lymphogranuloma venereum infection require an interprofessional team approach involving clinicians, mid-level practitioners, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. In most cases, clinicians diagnose and prescribe treatment, although they often require a consultation with infectious disease specialists. Pharmacists play a crucial role in verifying the appropriate selection and dosing of antibiotics, and they communicate any concerns or recommendations directly to the prescribing clinician or nursing team. This collaborative model promotes safe, effective, and patient-centered care.

The diagnosis and management of lymphogranuloma venereum infection require an interprofessional team approach involving clinicians, mid-level practitioners, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. In most cases, clinicians diagnose and prescribe treatment, although they often require a consultation with infectious disease specialists. Pharmacists play a crucial role in verifying the appropriate selection and dosing of antibiotics, and they communicate any concerns or recommendations directly to the prescribing clinician or nursing team. This collaborative model promotes safe, effective, and patient-centered care. Nurses play a key role in providing patient education and counseling to promote early symptom recognition and support preventive strategies—efforts that should be reinforced by both clinicians and pharmacists. Pharmacists are responsible for reviewing the patient's medication regimen for potential drug-drug interactions and promptly alerting the nursing staff or prescribing clinician if any are identified. Both nurses and pharmacists contribute to verifying treatment adherence, educating patients on proper medication use and dosing, and reporting any issues that may affect therapy. The clinician can then adjust the treatment plan as needed based on this feedback. These interprofessional strategies are essential for achieving optimal patient outcomes.